Resection Post-radio-embolization in Patients with Single Large Hepatocellular Carcinoma

Overview

Journal Hepatobiliary Surg Nutr

Publisher AME Publishing Company

Date 2024 Apr 15

PMID 38617477

Authors

Kevin Hakkakian

Nicolas Golse

Affiliations

Soon will be listed here.

Citing Articles

Development and validation of a nomogram to predict cancer-specific survival of patients with large hepatocellular carcinoma accepting surgical resection: a real-world analysis based on the SEER database.

Li L, Liu C, Li H, Yang J, Pu M, Zhang S J Gastrointest Oncol. 2024; 15(4):1657-1673.

PMID: 39279946 PMC: 11399871. DOI: 10.21037/jgo-24-285.

References

Tzedakis S, Sebai A, Jeddou H, Garin E, Rolland Y, Bourien H . Resection Postradioembolization in Patients With Single Large Hepatocellular Carcinoma. Ann Surg. 2023; 278(5):756-762. DOI: 10.1097/SLA.0000000000006061. View

Qu W, Ding Z, Qu X, Tang Z, Zhu G, Fu X . Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open. 2022; 6(5). PMC: 9499852. DOI: 10.1093/bjsopen/zrac114. View

Tomonari T, Tani J, Sato Y, Tanaka H, Tanaka T, Taniguchi T . Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2023; 15(21). PMC: 10650115. DOI: 10.3390/cancers15215221. View

Inarrairaegui M, Pardo F, Bilbao J, Rotellar F, Benito A, DAvola D . Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol. 2012; 38(7):594-601. DOI: 10.1016/j.ejso.2012.02.189. View

Baker T, Tabrizian P, Zendejas I, Gamblin T, Kazimi M, Boudjema K . Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group. HPB (Oxford). 2022; 24(7):1007-1018. DOI: 10.1016/j.hpb.2021.12.013. View

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

Llovet J, Castet F, Heikenwalder M, Maini M, Mazzaferro V, Pinato D . Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2021; 19(3):151-172. DOI: 10.1038/s41571-021-00573-2. View

Salem R, Gordon A, Mouli S, Hickey R, Kallini J, Gabr A . Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 151(6):1155-1163.e2. PMC: 5124387. DOI: 10.1053/j.gastro.2016.08.029. View

Qin S, Chen M, Cheng A, Kaseb A, Kudo M, Lee H . Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023; 402(10415):1835-1847. DOI: 10.1016/S0140-6736(23)01796-8. View

10.

Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A . Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology. 2022; 303(3):699-710. DOI: 10.1148/radiol.211806. View

11.

Salem R, Johnson G, Kim E, Riaz A, Bishay V, Boucher E . Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology. 2021; 74(5):2342-2352. PMC: 8596669. DOI: 10.1002/hep.31819. View

12.

Kaseb A, Hasanov E, Tran Cao H, Xiao L, Vauthey J, Lee S . Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022; 7(3):208-218. PMC: 8840977. DOI: 10.1016/S2468-1253(21)00427-1. View

13.

Zhu X, Huang C, Shen Y, Xu B, Ge N, Ji Y . Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma. Ann Surg Oncol. 2022; 30(5):2782-2790. PMC: 10085942. DOI: 10.1245/s10434-022-12530-z. View

14.

Kudo M . Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2022; 11(5):399-406. PMC: 9485978. DOI: 10.1159/000526163. View

15.

Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, De Baere T . Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2020; 6(1):17-29. DOI: 10.1016/S2468-1253(20)30290-9. View